硝普钠联合多巴胺治疗顽固性心衰的疗效研究  

Efficacy study of sodium nitroprusside combined with dopamine on refractory heart failure

作　　者：万保涛 陈树松 林松[2] WAN Bao-tao;CHEN Shu-song;LIN Song(Department of Cardiology,Laian Jianing Hospital,Chuzhou 239200,China)

机构地区：[1]滁州市来安家宁医院心内科,239200 [2]南京市第一医院心血管内科,210006

出　　处：《中国实用医药》2023年第8期17-20,共4页China Practical Medicine

基　　金：硝普钠联合多巴胺治疗顽固性心衰的疗效研究(项目编号:202003)。

摘　　要：目的研究顽固性心力衰竭(心衰)采取硝普钠联合多巴胺治疗的综合疗效以及用药安全性。方法34例顽固性心衰患者,随机分为对照组(16例)及治疗组(18例)。对照组实施常规抗心衰治疗,治疗组在对照组的基础上实施硝普钠联合多巴胺治疗。比较两组治疗效果、用药不良反应发生情况、治疗前后心功能指标[左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]及治疗后实验室指标[B型钠尿肽(BNP)、C反应蛋白(CRP)]。结果治疗组患者总有效率94.44%高于对照组的62.50%,差异有统计学意义(P<0.05)。治疗后,两组患者LVEF高于本组治疗前,LVEDD、LVESD小于本组治疗前,且治疗组患者LVEF(48.34±4.18)%高于对照组的(44.72±4.26)%,LVEDD(56.50±4.38)mm、LVESD(51.83±4.57)mm小于对照组的(59.92±4.30)、(55.63±4.60)mm,差异有统计学意义(P<0.05)。治疗组用药不良反应发生率为16.67%(3/18),与对照组的12.50%(2/16)比较,差异无统计学意义(P>0.05)。治疗组治疗后BNP(242.31±20.12)pg/ml与CRP(2.53±1.03)mg/L均低于对照组的(258.52±20.35)pg/ml、(3.85±1.09)mg/L,差异有统计学意义(P<0.05)。结论对顽固性心衰患者在常规抗心衰治疗的同时实施硝普钠联合多巴胺治疗,有助于提升疗效,改善实验室指标,保证用药安全性,有重要的临床推广与应用价值。Objective To study the comprehensive efficacy and safety of sodium nitroprusside combined with dopamine on patients with refractory heart failure.Methods A total of 34 patients with refractory heart failure were randomly divided into control group(16 cases)and treatment group(18 cases).The control group was treated with conventional anti-heart failure therapy,and the treatment group was treated with nitroprusside sodium and dopamine on the basis of the control group.Both groups were compared in terms of therapeutic effect,occurrence of adverse drug reactions,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]before and after treatment,and laboratory indexes[B-type natriuretic peptide(BNP),C-reactive protein(CRP)]after treatment.Results The total effective rate in the treatment group was 94.44%,which was higher than that of 62.50%in the control group,and the difference was statistically significant(P<0.05).After treatment,LVEF in the two groups was higher than that before treatment in this group,while LVEDD and LVESD were lower than those before treatment in this group;LVEF of(48.34±4.18)%in the treatment group was higher than that of(44.72±4.26)%in the control group;LVEDD of(56.50±4.38)mm and LVESD of(51.83±4.57)mm in the treatment group were smaller than those of(59.92±4.30)and(55.63±4.60)mm in the control group;the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the treatment group was 16.67%(3/18),and difference was not statistically significant compared with 12.50%(2/16)in the control group(P>0.05).BNP of(242.31±20.12)pg/ml and CRP of(2.53±1.03)mg/L in the treatment group were lower than those of(258.52±20.35)pg/ml and(3.85±1.09)mg/L in the control group,and the differences were statistically significant(P<0.05).Conclusion For patients with refractory heart failure,the combination of sodium nitroprusside and dopamine with conventional anti-heart fa

关 键 词：顽固性心力衰竭 硝普钠 多巴胺 心功能 实验室指标 

分 类 号：R541.6[医药卫生—心血管疾病]